Excalibur Management Corp Sells 60 Shares of Danaher Co. (NYSE:DHR)

Excalibur Management Corp reduced its position in shares of Danaher Co. (NYSE:DHR) by 2.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,987 shares of the conglomerate’s stock after selling 60 shares during the quarter. Excalibur Management Corp’s holdings in Danaher were worth $496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tsfg LLC increased its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. Cape Investment Advisory Inc. bought a new stake in shares of Danaher in the 4th quarter valued at about $25,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of Danaher in the 1st quarter valued at about $30,000. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DHR. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Jefferies Financial Group assumed coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. TD Cowen boosted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Finally, Wells Fargo & Company assumed coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Insider Buying and Selling at Danaher

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.7 %

DHR opened at $276.06 on Tuesday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The stock’s fifty day simple moving average is $265.25 and its 200 day simple moving average is $256.67. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a market cap of $199.37 billion, a PE ratio of 46.79, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.05 EPS. As a group, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.